J Bone Miner Res 24:153–161PubMed 240. Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394–402PubMed 241. Bucay N, Sarosi I, Dunstan CR et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Genes NVP-BGJ398 order Dev 12:1260–1268PubMed 242. Ziegler S, Kudlacek S, Luger A, Minar E (2005) Osteoprotegerin plasma concentrations correlate with severity of peripheral artery click here disease. Atherosclerosis 182:175–180PubMed 243. Mesquita M, Demulder A, Damry N, Melot C, Wittersheim E, Willems D, Dratwa M, Bergmann P (2009) Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med 47:339–346PubMed 244. Kobayashi-Sakamoto M, Hirose K, Isogai E, Chiba I (2004) NF-kappaB-dependent
induction selleckchem of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. Biochem Biophys Res Commun 315:107–112PubMed 245. Vik A, Mathiesen EB, Noto AT, Sveinbjornsson B, Brox J, Hansen JB (2007) Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 191:128–134PubMed 246. Helas S, Goettsch C, Schoppet M, Zeitz U, Hempel U, Morawietz H, Kostenuik PJ, Erben RG, Hofbauer LC (2009) Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 175:473–478PubMed 247. Hodsman AB, Bauer DC, Dempster DW et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703PubMed 248. Neer RM, Arnaud
CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N SPTLC1 Engl J Med 344:1434–1441PubMed 249. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5220PubMed 250. Antoniucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, Black DM (2007) Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab 92:942–947PubMed 251. Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr (2010) Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1–34 versus calcitriol and calcium. J Clin Endocrinol Metab 95:2680–2688PubMed 252.